Physician profile
Owen Kramer
NPI 1477086874
$10,409.10
in general payments reported to CMS, 2019-2025
30 companies · $3,329 in 2025
The $3,329 reported for 2025 was more than what 93% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $328 · 2021: $405 · 2022: $1,232 · 2023: $1,955 · 2024: $2,696 · 2025: $3,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,679 · Education: $285 · Travel and Lodging: $16.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,678.84 |
| Education | $284.73 |
| Travel and Lodging | $16.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,983.59 | 2019-2025 | |
| Lilly USA, LLC | $1,281.61 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $1,184.40 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $881.93 | 2021-2025 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $860.41 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $647.35 | 2022-2025 | |
| Galderma Laboratories, L.P. | $479.94 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Pfizer INC. | $435.57 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $398.67 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $371.73 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $344.24 | 2024-2025 | |
| Incyte Corporation | $314.92 | 2022-2025 | Opzelura |
| Amgen INC. | $260.05 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $215.56 | 2022-2024 | Vtama |
| Ucb, INC. | $113.79 | 2024-2025 | Bimzelx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $97.33 | 2019 | |
| Leo Pharma INC. | $89.37 | 2025 | Adbry, Anzupgo |
| Botanix Sb INC | $76.18 | 2025 | Sofdra |
| Smith+Nephew, INC. | $60.19 | 2025 | Grafix Pl |
| Organon LLC | $55.79 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.84 | 2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $38.83 | 2024-2025 | Ycanth |
| Almirall LLC | $38.29 | 2021-2022 | |
| Mimedx Group, INC. | $24.08 | 2025 | |
| Sandoz INC. | $23.58 | 2024 | Hyrimoz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.02 | 2024 | Jublia, Cabtreo, Arazlo |
| Sanofi-Aventis U.S. LLC | $16.80 | 2021 | |
| Celgene Corporation | $15.96 | 2019 | |
| Merz North America, INC. | $15.32 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Owen Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.